The estimated Net Worth of Shane Ward is at least $711 millier dollars as of 11 March 2024. Mr. Ward owns over 20,473 units of Bellicum Pharmaceuticals Inc stock worth over $14,858 and over the last 8 years he sold BLCM stock worth over $88,946. In addition, he makes $606,859 as Corporate Secretary et Chief Legal and Strategy Officer at Bellicum Pharmaceuticals Inc.
Shane has made over 7 trades of the Bellicum Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 20,473 units of BLCM stock worth $13,717 on 11 March 2024.
The largest trade he's ever made was selling 20,473 units of Bellicum Pharmaceuticals Inc stock on 11 March 2024 worth over $13,717. On average, Shane trades about 1,873 units every 118 days since 2016. As of 11 March 2024 he still owns at least 198,770 units of Bellicum Pharmaceuticals Inc stock.
You can see the complete history of Mr. Ward stock trades at the bottom of the page.
Shane M. Ward J.D. serves as Corporate Secretary, Chief Legal and Strategy Officer of the Company. He is our Corporate Secretary since May 2018. He previously served as our Senior Vice President, General Counsel from May 2018 to October 2019. From April 2015 to May 2018, Mr. Ward served as Senior Vice President and General Counsel for Versartis, Inc., a publicly traded biopharmaceutical company, where he built the legal, compliance and quality assurance teams and infrastructure in preparation for Versartis’ first BLA submission and potential commercialization. From November 2012 to March 2015, Mr. Ward served as Vice President and Associate General Counsel for Dynavax Technologies Corporation, a publicly traded clinical-stage biopharmaceutical company, where his responsibilities included management of all legal matters. Prior to that, he served in roles of increasing responsibility at Human Genome Sciences, Inc. including as Associate General Counsel. Earlier in his career, Mr. Ward was a senior in-house attorney with commercial pharmaceutical companies Gilead Sciences and Abbott Laboratories. He began his legal career as an associate for the international law firm Sidley Austin LLP. Mr. Ward earned his B.A from the University of Virginia, and his J.D. from Georgetown University Law Center and is admitted to practice law in California, Illinois and Virginia.
As the Corporate Secretary et Chief Legal and Strategy Officer of Bellicum Pharmaceuticals Inc, the total compensation of Shane Ward at Bellicum Pharmaceuticals Inc is $606,859. There are 2 executives at Bellicum Pharmaceuticals Inc getting paid more, with Richard Fair having the highest compensation of $1,732,890.
Shane Ward is 45, he's been the Corporate Secretary et Chief Legal and Strategy Officer of Bellicum Pharmaceuticals Inc since 2019. There are 14 older and 2 younger executives at Bellicum Pharmaceuticals Inc. The oldest executive at Bellicum Pharmaceuticals Inc is Dr. Alan K. Smith Ph.D., 63, who is the Chief Scientific Officer.
Shane's mailing address filed with the SEC is 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA, 92121.
Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli... et Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.
bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: